Eight-weekly intravenous antibiotics is beneficial in severe bronchiectasis

QJM: An International Journal of Medicine

Volumn 106, Issue 1, 2013, Pages 27-33

  Mandal, P ^a   Sidhu, M K ^b   Donaldson, L S ^b   Chalmers, J D ^a   Smith, M P ^b   Turnbull, K ^b   Scott, J ^b   Hill, A T ^a,b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; C REACTIVE PROTEIN; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BODY MASS; BRONCHIECTASIS; CLINICAL ARTICLE; DISEASE EXACERBATION; ERYTHROCYTE SEDIMENTATION RATE; ESCHERICHIA COLI INFECTION; EXERCISE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; FUNCTION TEST; HAEMOPHILUS INFECTION; HUMAN; INCREMENTAL SHUTTLE WALK TEST; LEUKOCYTE COUNT; MALE; MIXED INFECTION; MORAXELLACEAE INFECTION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSEUDOMONAS INFECTION; QUALITY OF LIFE; QUESTIONNAIRE; SPUTUM; SPUTUM CULTURE; STAPHYLOCOCCUS INFECTION; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 84871557558     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcs173     Document Type: Article

References (26)

1. Roguin A. Rene Theophile Hyacinthe Laennec (1781-1826): the man behind the stethoscope. Clin Med Res 2006; 4:230-5.
2. Stockley RA, Hill AL, Morrisson HM, Starkie CM. Elastolytic activity of sputum and its relation to purulence and to lung function in patients with bronchiectasis. Thorax 1984; 39:408-13.
3. Hill AT, Campbell EJ, Hill SL, Bayley DL, Stockley RA. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000; 109:288-95.
4. Angrill J, Agusti C, de Celis R, Rano A, Gonzalez J, Sole T, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57:15-9.
5. Angrill J, Agusti C, de Celis R, Filella X, Rano A, Elena M, et al. Bronchial inflammation and colonization in patients with clinically stable bronchiectasis. Am J Respir Crit Care Med 2001; 164:1628-32.
6. Pasteur MC, Bilton D, Hill AT. British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax. 2010; 65(Suppl. 1):i1-58.
7. Ho PL, Chan KN, Ip MS, Lam WK, Ho CS, Yuen KY, et al. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest 1998; 114:1594-8.
8. Wilson CB, Jones PW, O'Leary CJ, HAnsell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997; 10:1754-60.
9. Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead MA. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J 1996; 9:1601-4.
10. Frederiksen B, Lanng S, Koch C, Hoiby N. Improved survival in the Danish Center-treated cystic Ebrosis patients: Results of aggressive treatment. Pediatric Pulmonology 1996; 21:153-8.
11. Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003; 58:339-43.
12. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation: the St Georges' Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-7.
13. Murray MP, Turnbull K, Macquarrie S, Pentland JL, Hill AT. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J 2009; 34:125-31.
14. Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R. Validation of the St George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997; 156:536-41.
15. Guidelines for the measurement of respiratory function. Recommendations of the British Thoracic Society and the Association of Respiratory Technicians and Physiologists. Respir Med 1994; 88:165-94.
16. Singh SJ, Morgan MD, Scott SC, Walters D, Hardman AE. The development of a shuttle walking test of disability in patients with chronic airways obstruction. Thorax 1992; 47:1019-24.
17. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med 2006; 100:2183-9.
18. Curtis JR, Martin DP, Martin TR. Patient-assessed health outcomes in chronic lung disease: what are they, how do they help us, and where do we go from here? Am J Respir Crit Care Med 1997; 156:1032-9.
19. Mahler DA. How should health-related quality of life be assessed in patients with COPD? Chest 2000; 117 (Suppl. 2):54 S-7 S.
20. Murray MP, Pentland JL, Hill AT. A randomised crossover trial of chest physiotherapy in non-cystic fibrosis bronchiectasis. Eur Respir J. 2009; 34:1086-92.
21. Murray MP, Govan JR, Doherty CJ, Simpson AJ, Wilkinson TS, Chalmers JD, et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2011; 183:491-9.
22. Martinez-Garcia MA, Soler-Cataluna JJ, Perpina-Tordera M, Roman Sanchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic Ebrosis bronchiectasis. Chest 2007; 132:1565e72.
23. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Gallagher M, Holmes PW. Outcome in adult bronchiectasis. COPD 2005; 2:27-34.
24. Breen L, Aswani N. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev 2001; 4:CD002767.
25. Brett MM, Simmonds EJ, Ghoneim ATM, Littlewood JM. The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic Ebrosis. Arch Dis Childhood 1992; 67:1086-8.
26. Elborn JS, Prescott RJ, Stack BHR, Goodchild MC, Bates J, Pantin C, et al. Elective versus symptomatic antibiotic treatment in cystic Ebrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000; 55:355-8.